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Introduction: We investigated Nestin expression in triple-negative breast cancer and examined how the modulation
of Nestin expression affects cell cycle progression, survival, invasion and regulatory signaling in breast cancer stem cells
(CSC) in vitro.
Methods: Nestin expression in 150 triple-negative breast cancer specimens were examined by immunohistochemistry.
The role of Nestin expression in tumorigenesis was examined by assaying naturally occurring Nestinhigh/Nestinlow CSC
from 12 breast cancer tissues, as well as CSC from 26 clinical specimens, where Nestin overexpression and silencing
was achieved by genetic manipulation, for their ability to form mammospheres and induce solid tumors. Cell cycle
progression, spontaneous apoptosis and invasiveness of Nestin-silenced breast CSC were investigated by flow cytometry
and transwell assays. The relative levels of expression of epithelial-mesenchymal transition (EMT) and Wnt/β-catenin
pathway-related molecules were determined by western blotting.
Results: Nestin expression was significantly associated with poor survival in patients with triple-negative breast cancer
(P = 0.01). Nestinhigh breast CSC rapidly formed typical mammospheres in vitro. Nestinhigh, but not Nestinlow CSC, efficiently
formed solid tumors in vivo. Nestin silencing induced cell cycle arrest at G2/M (52.03% versus 19.99% in controls) and
promoted apoptosis (36.45% versus 8.29% in controls). Nestin silencing also inhibited breast CSC invasiveness, and was
associated with significantly upregulated E-cadherin, while N-cadherin, vimentin, a-smooth muscle actin (a-SMA), matrix
metalloproteinase-2 (MMP-2), MMP-9 and vascular endothelial growth factor (VEGF) expression was downregulated
(P <0.05 for all). Nestin silencing also upregulated Axin, glycogen synthase kinase-3 beta (GSK-3β), adenomatous
polyposis coli (APC), and peroxisome proliferator-activated receptor alpha (PPARa), and downregulated β-catenin,
c-Myc, cyclin D and MMP-7 expression in CSC. Inhibition of the Wnt/β-catenin pathway mitigated mammosphere
formation in Nestinhigh CSC, while inhibition of GSK-3β promoted the mammosphere formation in Nestinlow CSC
(P <0.05 for all).
Conclusions: Our data indicates that Nestin positively regulates the proliferation, survival and invasiveness of
breast CSC by enhancing Wnt/β-catenin activation.Introduction
Breast cancer is the most common malignancy in women,
and its incidence is increasing worldwide. The disease re-
mains a huge threat to women’s health. Patients with
‘triple-negative’ breast cancer, referring to absence in the
expression of estrogen receptor (ER), progesterone receptor* Correspondence: angel-s205@163.com
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(HER2), are insensitive to hormonal therapy or HER2-
targeted agents [1]. These patients are also at increased
risk for relapse and metastasis of breast cancer, which is
often incurable and a leading cause of female mortality
[2-4]. Unfortunately, there is currently no effective therapy
to control the recurrence and metastasis of triple-negative
breast cancer. Therefore, understanding the molecular
mechanisms underlying the recurrence and metastasis of
triple-negative breast cancer may reveal new therapeutictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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patients with triple-negative breast cancer.
Nestin, an intermediate filament protein, was initially
identified as a neural stem cell marker [5-7]. Nestin ex-
pression has been detected in malignant tumor tissues,
and has been implicated in the development and metas-
tasis of malignant tumors, such as brain malignancies
[8,9], melanoma [10], colorectal [11], prostate [12], and
pancreatic cancers [13]. Nestin overexpression has been
reported in metastatic breast cancers, (especially in
triple-negative breast cancers) [7,14-17], and has been
associated with poor prognosis in a Caucasian breast
cancer cohort [16]. However, this association has not
been verified in Chinese patients with triple-negative
breast cancer.
Cancer stem cells (CSC) play an important role in the
development and metastasis of breast cancer [18-20].
Breast CSC exhibit potent tumorigenicity, and implant-
ation with a few ESA+CD44+CD24− lineage− breast CSC
has been demonstrated to induce solid tumor formation
in severe combined immunodeficiency (SCID) mice [21].
Our previous study shows that Nestin and other stem-
ness factors are expressed in breast cancer tissues, and
that their expression is associated with poor survival of
patients with breast cancer [22]. These findings suggest
that Nestin may regulate the development and metasta-
sis of breast cancers. However, little is known about the
molecular mechanisms by which Nestin regulates cell
proliferation, survival, and invasiveness of breast CSC.
Previous studies have shown that the Wnt/β-catenin
pathway is crucial for the development and progression
of breast cancer [23,24]. High levels of Wnt receptor
and co-receptor expression, as well as aberrant activa-
tion of β-catenin, have been detected in breast cancer
tissues. Downregulation of the Wnt/β-catenin pathway
can inhibit the epithelial-mesenchymal transition (EMT)
and reduce spontaneous invasion of breast cancer cells
[25,26]. Therapeutic targeting of the porcupine (PORCN)
protein suppresses Wnt/β-catenin activation, and signifi-
cantly reduces the spontaneous development of mammary
tumors in transgenic mice [27]. In addition, aberrant activa-
tion of the Wnt/β-catenin pathway has been associated
with the development of resistance to radiotherapy and
chemotherapy in breast cancer [28,29]. The Wnt/β-catenin
pathway is also important for self-renewal and migration of
breast CSC [30,31]. β-catenin is expressed constitutively in
many types of tumor cells. Increased Wnt/β-catenin activa-
tion enhances the tumorigenicity of breast CSC [32]. In the
absence of Wnt binding to its receptor, β-catenin forms a
degradation complex that includes the Axin, adenomatous
polyposis coli (APC), and glycogen synthase kinase-3 beta
(GSK-3β) proteins. GSK-3β/ casein kinase 1 (CK1) phos-
phorylates β-catenin, targeting it for β-TrCP1-mediated
degradation, which is positively regulated by peroxisomeproliferator-activated receptor alpha (PPARa) and PPARb.
Binding of Wnt to its receptor and co-receptors causes the
activation of Dishevelled (Dsh) proteins by phosphorylation.
Activated Dsh then recruits GSK-3β, releasing β-catenin
and promoting the nuclear translocation of β-catenin.
Subsequently, β-catenin binds to the Tcf and Lef transcrip-
tion factors in the nucleus, leading to the transcription of
downstream genes, including c-Myc, cyclin D, and MMP-7.
Although Wnt/β-catenin activation can promote the ex-
pression of various stemness factors, including Nestin, little
is known about whether the modulation of Nestin expres-
sion can affect Wnt/β-catenin activation in breast CSC.
In the present study, we first characterized Nestin ex-
pression in 150 tumor specimens from patients with
triple-negative breast cancer, and analyzed the potential
association between levels of Nestin expression and the
survival of patients. We isolated CD44+CD24− CSC
from 26 triple-negative breast cancer tissues to gener-
ate Nestin-overexpressing (Nestin+), Nestin-silencing
(Nestin-si), and control (Nestin-c) CSC. We also
isolated CD44+CD24−, cell surface Nestinhigh, or Nestinlow
CSC from 12 triple-negative breast cancer tissues. Subse-
quently, we characterized the ability of these CSC to form
mammospheres in vitro, and of Nestinhigh or Nestinlow to
induce tumors in SCID mice. We examined the effects of
Nestin silencing on the cell cycle, survival, and apoptosis of
breast CSC, and explored potential mechanisms underlying
the action of Nestin in the tumorigenicity of breast CSC.
Our data suggest that Nestin may promote the prolifera-




A total of 150 breast cancer samples were obtained from
patients with ER-/PR-/HER2- (triple-negative) breast
cancer at the Department of Breast Surgery of the First
Affiliated Hospital of China Medical University between
January 2001 and December 2006. In addition, 12 pa-
tients with triple-negative breast cancer were recruited
and ESA+CD44+CD24− lineage− CSC in the resected
breast cancer tissues were isolated. The CSC were
stained with anti-Nestin and sorted for cell surface
positive Nestinhigh or negative Nestinlow CSC. Patients
with triple-negative breast cancer were diagnosed by
histological examination of tissue samples, and they
underwent radical surgery in the Department of Breast
Surgery. The inclusion criteria were: (a) curative surgical
resection; (b) pathological examination of the resected
tumor; (c) pathological examination of >15 lymph nodes
after surgery; and (d) availability of a complete medical
record. The demographic and clinical data for individual
patients were obtained from medical records. Individuals
with breast cancer were excluded if they did not fulfill
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obtained from individual patients and the experimental
protocol was approved by the Ethics Committee of
China Medical University.
Immunohistochemical staining
Individual breast cancer tissue samples were fixed in 10%
neutralized formalin (pH 7.0) and paraffin-embedded. The
tissue sections (4 mm) were dewaxed, rehydrated, and
treated with 3% H2O2 in methanol, followed by incubation
overnight with primary anti-Nestin antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Subsequently,
the tissue sections were incubated with Multi-Link bio-
tinylated swine anti-goat/mouse/rabbit immunoglobu-
lin (Ig)G (Dako, Carpinteria, CA, USA). After washing
the cells, the bound antibodies were detected using
horseradish peroxidase (HRP)-conjugated avidin-biotin
complex (1:1000 dilution, Vector Laboratories, Burlin-
game, CA, USA), and visualized using 3,3-diaminoben-
zidine (DAB), followed by counterstaining with Gill’s
hematoxylin.
The intensity of anti-Nestin staining was scored semi-
quantitatively. Cells with yellow to brown cytoplasmic
staining were considered to be Nestin+ cells. Nestin ex-
pression levels in individual tumor tissues were assigned
a score based on the following criteria: 0 if <1% neoplas-
tic cells are Nestin+; 1+ if neoplastic cells were 1 to 10%
Nestin+; and 2+ if ≥10% Nestin+ neoplastic cells. Individ-
ual sections with 1+ or 2+ anti-Nestin staining were
considered positive.
Preparation and characterization of breast CSCs
Thirty-eight freshly resected breast tumor specimens
were obtained for the preparation of CSC, as described
previously [33]. Briefly, fresh breast tumor specimens
were cut into small pieces and were digested with 1 mg/
mL of collagenase type III (5 mL/g tissue, Worthington
Biochemical, Lakewood, NJ, USA) in 5% fetal bovine
serum (FBS) containing RPMI medium at 37°C for 2 h,
and centrifuged. The tumor cells (106/tube) were se-
quentially stained with FITC-anti-CD2, APC-anti-CD3,
PE-anti-CD10, FITC-anti-CD16, APC-anti-CD18, PE-
anti-CD31, and FITC-anti-CD326 lineage markers, as
well as 7-AAD (BD Biosciences Pharmingen, San
Diego, CA, USA). Lineage+ and dead cells were first
eliminated by flow cytometric sorting. Subsequently,
the unstained lineage-negative cells were stained with
PE-anti-CD24 and FITC-anti-CD44, and CD44+CD24−
breast CSC were purified by flow sorting. Finally, the
sorted CD44+CD24− breast CSC were stained with
rabbit anti-Nestin (#N5413; Sigma-Aldrich, St. Louis,
MO, USA) and then with APC-anti-rabbit IgG to allow
sorting of the cell surface positive (Nestinhigh) and
negative (Nestinlow) breast CSC.Transfection
The purified CD44+CD24− breast CSC from 26 specimens
were transfected with human Nestin-specific (sc-36032, a
mixture of sc-36032A, sense 5′-CGAGGUCUUUAGAA
GAAGAtt-3′ and antisense 5′-UCUUCUUCUAAAGAC
CUCGtt-3′; sc-36032B, sense 5′-GCCUUUAGAUCUCU
AGAAAtt-3′ and antisense 5′- UUUCUAGAGAUCUA
AAGGCtt-3; sc-36032C, sense 5′- GGCAAUGAAUCC
UCUAGAAtt-3′ and antisense 5′-UUCUAGAGGAUUC
AUUGCCtt-3′) or control small interfering RNA (siRNA)
(sc-37007, Santa Cruz Biotechnology) using Lipofectamine
2000 Reagent (Invitrogen, Carlsbad, CA, USA), according
to the manufacturers’ protocols. Nestin-silenced (Nestin-si)
and control siRNA-transfected (Nestin-c) CSC were har-
vested at 24 or 48 h posttransfection, and the efficacy of
Nestin silencing was determined by western blotting. To
generate Nestin overexpressing CSC, CD44+CD24− cells
were transfected with pIRES-Nestin-EGFP (constructed in
our laboratory) or control pIRES-EGFP (Clontech Labora-
tory, Mountain View, CA, USA) for 48 h. EGFP+ Nestin+
cells were then isolated by flow sorting. A preparation of
EGFP+Nestin+ CSC with a purity of >95% was used for the
subsequent experiments.Mammosphere formation and in vivo xenograft assays
Nestin+, Nestin-si, Nestin-c, Nestinhigh, Nestinlow, and un-
manipulated control breast CSC (5,000 cells/mL) were cul-
tured in triplicate in Complete MammoCult™ Medium in
six-well ultralow attachment plates (Corning Life Sciences,
Tewksbury, MA, USA) for five days in the presence of
human leukemia inhibitory factor (LIF, 50 ng/mL), an en-
hancer of mammosphere formation in vitro. The number
of mammospheres (>50 mm in a dimension) in individual
wells were counted in a blinded manner. In addition,
Nestinhigh CSC in the presence of LGK974 (1 nM),
Nestinlow CSC in the presence of SB216763 (5 μM,
Selleckchem, Houston, TX, USA), and control CSC in
the presence of a vehicle were tested for the formation
of mammospheres in vitro.
Eight-week-old female C57BL/6 SCID mice were ob-
tained from The Jackson Laboratory (Beijing, China)
and housed in a specific pathogen-free facility on our
campus. C57BL/6 SCID mice were implanted with
different numbers (103 to 105/mouse) of the purified
ESA+CD44+CD24−lineage− Nestinhigh, Nestinlow, and
control CSC in 50 ml phosphate-buffered saline (PBS)
in their mammary fat pads. The development of solid
tumors was monitored for up to 28 days post xeno-
transplantation. The levels of Nestin expression in the
dissected tumors were determined by western blotting.
The experimental protocol was approved by the Ani-
mal Care and Research Committee of China Medical
University.
Table 1 The sequences of primers
Genes Sequences Sizes (bp)
Axin F: 5′-CTCCAgTAgACggTACAgCgAAg-3′ 90
R: 5′-gCATAgCCggCATTgACATA-3′
GSK-3β F: 5′-CTACCAAATgggCGAGCATGAG-3′ 112
R: 5′-CTGCTTGAATCCGAGCATGAG-3′
Nestin F: 5′-CTCCAAGAATGGAGGCTGTAGGAA-3′ 75
R: 5′-CCTATGAGATGGAGCAGGCAAGA-3′
APC F: 5′-CCTCTGAAACAGTGCTGAACTTG-3′ 158
R: 5′-CACCTGGTACTTGGCCACTA-3′
β-catenin F: 5′-GTACGTCCATGGGTGGGACA-3′ 80
R: 5′-GGCTCCGGTACAACCTTCAACTA-3′
β-Actin F: 5′-TGGCACCCAGCACAATGAA-3′ 186
R: 5-CTAAGTCATAGTCCGCCTAGAAAGCA-3′
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Following transfection for 96 h, the Nestin-si and
Nestin-c breast CSC were fixed by treatment with 70%
cold ethanol, followed by staining with propidium iodide
(PI, 30 μg/mL). The percentages of CSC in each phase of
the cell cycle were determined by flow cytometry on a
FACS Calibur device (BD Biosciences, San Jose, CA, USA).
The Nestin-si and Nestin-c breast CSC were stained with
FITC-Annexin V (2.5 μg/mL) and PI (5 μg/mL), and the
percentages of spontaneously apoptotic Nestin-si and
Nestin-c breast CSC were determined by flow cytometry.
Transwell invasion assay
Nestin-si and Nestin-c breast CSC (1 × 105 cells/well)
were cultured in triplicate at 37°C for 1.5 h in the upper
chambers of transwell plates (Corning) that had been
loaded with 60 to 80 μL of diluted Matrigel (BD Biosci-
ences). The cells that had migrated into the lower cham-
ber were fixed with 95% ethanol and stained with crystal
violet in gluteraldehyde, followed by visualization. The
number of migrated cells in 10 random fields (magnifi-
cation 400×) of each chamber were counted in a blinded
manner.
Quantitative reverse transcription PCR
The levels of Nestin, Axin, GSK-3β, APC, and β-catenin
mRNA transcripts relative to β-actin were determined
by quantitative reverse transcription PCR (qRT-PCR).
Briefly, total RNA was isolated from Nestin-si and Nestin-c
CSC using Trizol reagent, and reverse-transcribed into
cDNA using the RevertAid™ First Strand cDNA synthesis
kit (Fermentas, Pittsburgh, PA, USA), according to the
manufacturer’s instructions. The real-time PCR was
performed using the SYBR Green PCR Master Mix and
specific primers (Table 1) on an Applied Biosystems
7500 Fast Real-Time PCR System (Applied Biosystems,
Carlsbad, CA, USA). The amplification was performed
at 95°C for 5 min and then 40 cycles of 94°C for 15 s,
55°C for 20 s, 72°C for 20 s, followed by 72°C for 7 min.
The levels of mRNA transcripts were analyzed by the
2-ΔΔCt method. The relative levels of each gene tran-
script relative to β-actin in Nestin-c CSC were desig-
nated as 1.
Western blot analysis
Nestin-si and Nestin-c breast CSC were collected 48 h
posttransfection and lysed in lysis buffer, followed by
centrifugation. After quantification of protein concentra-
tions using a BCA assay (Santa Cruz Biotechnology), the
individual cell lysates (30 mg/lane) were separated by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto polyvinylidene fluor-
ide (PVDF) membranes. The membranes were blocked
with 5% fat-free milk powder in TBST and incubatedwith rabbit anti-Nestin, mouse anti-GSK-3β, anti-
phosphorylated GSK-3β, anti-Axin, anti-APC (1:500;
Cell Signaling Technology, Beverly, MA, USA), mouse
anti-matrix metalloproteinase-2 (MMP-2), anti-MMP9
(1:400), anti-vimentin, anti-vascular endothelial growth fac-
tor (VEGF) (1:800), mouse anti-a-smooth muscle actin
(a-SMA) (1:400), goat anti-E-cadherin (1:500; Santa Cruz
Biotechnology), rabbit anti-N-cadherin (1:500), and rabbit
anti-β-actin (1:5000; Abcam, Cambridge, UK) overnight at
4°C, respectively. After being washed, the bound antibodies
were detected by incubation with HRP-conjugated anti-
rabbit, anti-mouse, or anti-goat IgG at room temperature
for 1 h, and visualized using enhanced chemiluminescence
(Santa Cruz Biotechnology). Purified mouse, rabbit, or goat
IgG were used as the negative controls. The levels of target
proteins relative to β-actin were determined using the
ImmuNe software. Furthermore, nuclear and cytoplasmic
proteins were extracted from Nestin-si and Nestin-c CSC
and subjected to western blot analysis. The relative levels of
Nestin expression in the purified Nestinhigh, Nestinlow, and
unsorted control CSC as well as the dissected tumors from
SCID mice that had been implanted with Nestinhigh, Nes-
tinlow, or control CSC were also analyzed by western
blotting.Statistical analysis
Data are presented as mean ± standard deviation (SD).
Difference between groups was analyzed using Stu-
dent’s t test or the chi-square test. The cumulative
survival of patients with Nestin+ or Nestin− triple-
negative breast cancer was estimated using the Kaplan-
Meier method, and analyzed using the log-rank test.
All the statistical analyses were performed using the
SPSS statistics 16.0 software package (SPSS Inc, Chicago,
IL, USA). A P value of <0.05 was considered statistically
significant.
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Nestin expression is associated with poor survival in
patients with triple-negative breast cancer
Nestin is an intermediate filament protein expressed by
neural precursors, muscle, and stem cells [34], and has
been shown to regulate cell proliferation. Our previous
study showed that Nestin is expressed in human breast
cancer tissue, and that its expression was associated with
lymph node metastasis in a cohort of breast cancer pa-
tients [16]. To further understand the role of Nestin
in the development and progression of triple-negative
breast cancer, we characterized the levels of Nestin expres-
sion in 150 specimens from patients with triple-negative
breast cancer by immunohistochemistry (Figure 1A-C).
Nestin expression was detected in myoepithelial cells in all
of the matched adjacent nontumor areas (Figure 1A) and in
the cytoplasm of tumor cells in 41 specimens (27.33%,
Figure 1B and C), consistent with our previous observations
[16]. Survival analysis indicated that the survival of patients
with Nestin+ triple-negative breast cancer was significantly
reduced when compared with Nestin− triple-negative breast
cancer (P = 0.01, Figure 1D). These results further support
a notion that Nestin regulates breast cancer progression,
and suggest that Nestin expression may serve as a prognos-
tic marker in patients with triple-negative breast cancers.Figure 1 Nestin expression is associated with poor survival in patient
surgically resected breast tissue samples from patients with triple-negative
estimated using the Kaplan-Meier method, and the association between su
are representative images (400× magnification) and the cumulative surviva
in the surrounding nontumor areas; (B, C) negative and positive anti-Nestin
staining). (D) Cumulative survival of patients with triple-negative breast canNestinhigh breast CSC exhibit an enhanced tumorigenicity
Breast CSC express Nestin and are crucial for the develop-
ment and progression of breast cancer [35]. To understand
how Nestin regulates the proliferation and migration of
breast CSC, we analyzed the expression of Nestin in ESA+
CD44+CD24−lineage− CSC. We found that the proportion
of CD44+CD24− Nestinhigh CSC (57.45 ± 18.27%) were sig-
nificantly higher than that of CD44+CD24− Nestinlow CSC
(42.55 ± 16.4) in the 12 specimens isolated from patients
with triple-negative breast cancer (P <0.05, Figure 2A).
Western blot analysis indicated that the relative levels
of Nestin expression in Nestinhigh CSC were signifi-
cantly higher than that of control CSC, and signifi-
cantly higher than that in Nestinlow CSC (Figure 2B).
Furthermore, Nestinhigh CSC effectively formed mam-
mospheres, with the mean size and numbers of mam-
mospheres significantly greater than that of the control
CSC (Figure 2C). In contrast, the Nestinlow CSC failed
to form typical mammospheres, with the mean size of
mammospheres significantly smaller than that of con-
trol CSC. Next, we tested the effect of Nestin expres-
sion on the tumorigenicity of breast CSC in vivo. We
found that implantation of 103 Nestinhigh CSC resulted
in tumor formation in 4 out of 10 C57BL/6 SCID mice,
and the rates of tumor formation by Nestinhigh CSCs with triple-negative breast cancer. Nestin expression in 150
breast cancer was examined by immunohistochemistry. Survival was
rvival and Nestin expression was analyzed using the log-rank test. Data
l of 150 patients. (A) Positive anti-Nestin staining in myoepithelial cells
staining in breast tumors (white arrow indicates positive cytoplasmic
cer.
Figure 2 Nestinhigh breast CSC have potent tumorigenicity. The isolated breast CD44+CD24− CSC from 12 freshly resected breast cancer
tissues were stained with anti-Nestin, and the Nestin+ and Nestin− breast CSC were purified as Nestinhigh or Nestinlow CSC by flow cytometry,
respectively. The levels of Nestin expression in Nestinhigh, Nestinlow, and unstained control CSC were determined by western blotting, and these
CSC were tested for their capacity to form mammospheres in vitro and to induce solid tumors in vivo. Finally, the levels of Nestin expression in
the solid tumors induced by Nestinhigh, Nestinlow, or control CSC were determined by western blotting. Data are representative charts and images,
and expressed as the mean ± SD of each group of samples (n = 12 per group). (A) Flow cytometric analysis of CSC. (B) Western blot analysis of
the levels of Nestin expression. (C) Mammosphere formation. (D) The rates of tumor formation in SCID mice (n = 10 animals per group) from
three separate experiments. (E) Western blot analysis of Nestin expression in the formed tumors (n = 2 to 10 per group). CSC, cancer stem cell;
SCID, severe combined immunodeficiency; SD, standard deviation.
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plantation with 104 control CSC or 105 Nestinlow CSC
was required to induce tumors (2 out of 10 mice,
Figure 2D). More importantly, the relative levels of
Nestin expression in the formed solid tumors from the
different types of CSC was similar to that of the corre-
sponding type of injected CSC (Figure 2E). These data indi-
cate that Nestinhigh CSC had at least 100-fold greater
tumorigenicity than Nestinlow CSC in our experimental sys-
tem. Taken together, the rapid formation of mammospheres
in vitro and the efficient induction of solid tumors in vivo
clearly demonstrated that higher levels of Nestin expression
enhanced the tumorigenicity of CSC, which may contribute
to the progression and metastasis of triple-negative breast
cancer.Nestin silencing induces cell cycle arrest and apoptosis in
breast CSC
To further examine the effect of Nestin expression on CSC,
CD44+CD24− CSC were purified and transfected with
pNestin-EGFP, control siRNA, or Nestin-specific siRNA to
generate Nestin+, Nestin-c, and Nestin-si CSC, respectively.
Compared to control Nestin-c CSC, Nestin+ CSC expressed
higher levels of Nestin while Nestin-si CSC expressed much
lower levels of Nestin at 24 h posttransfection, confirming
Nestin overexpression and silencing, respectively (Figure 3A
and B). Nestin-si CSC did not effectively form typical mam-
mospheres, while Nestin+ CSC under the same conditions
formed numerous mammospheres >50 mm in diameter
(Figure 3C), suggesting that increased levels of Nestin ex-
pression enhanced the proliferation of breast CSC in vitro.
Figure 3 Nestin silencing inhibits the mammosphere formation, induces cell cycle arrest at G2/M and promotes apoptosis in breast
CSC. The isolated CD44+CD24− breast CSC from 26 specimens were transfected with control siRNA, Nestin-specific siRNA, pIRES-Nestin-EGFP, or
control pIRES-EGFP to generate Nestin-c, Nestin-si, Nestin+ or Nestin-EGFP cells. The Nestin-c, Nestin-si, and Nestin+ CSC were tested for the levels
of Nestin expression by western blotting and for their ability to form mammospheres in vitro. Their cell cycling progression and spontaneous
apoptosis were determined by flow cytometry. Data are representative charts and images, and expressed as the mean ± SD of each group (n = 26
per group). (A). Flow cytometric analysis of CD44+CD24− CSC. (B) Western blot analysis of Nestin expression in breast CSC. Nestin-EGFP and
Nestin-c control cells showed similar levels of Nestin expression (data not shown). (C) The mammosphere formation. (D) Cell cycle analysis of
Nestin-si and Nestin-c breast CSC; (E) apoptotic Nestin-si and Nestin-c breast CSC. *P <0.05 vs. the control. CSC, cancer stem cell; SD, standard
deviation; siRNA, small interfering RNA.
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Nestin-si CSC at G2/M phases and apoptotic Nestin-si
CSC were significantly higher than that of Nestin-c controls
(52.03% vs. 19.99% for cells at G2/M; 43.53 ± 4.78% vs.
16.24 ± 3.22% for apoptotic cells, P <0.01 for both,
Figure 3D and E). Thus, knockdown of Nestin expres-
sion induced CSC cycle arrest at G2/M and promoted
spontaneous CSC apoptosis in vitro, further supporting
the hypothesis Nestin promoted the proliferation and
survival of breast CSC.
Nestin silencing inhibits the migration of breast CSC by
downregulating the expression of EMT-related genes
Cancer metastasis is associated with the poor survival of
patients with triple-negative breast cancer. We therefore
tested the effect of Nestin silencing on the invasiveness
of breast CSC using a transwell migration assay. We
found that the numbers of migrated Nestin-si CSC were
significantly less than control Nestin-c CSC (P <0.05,
Figure 4A), indicating that Nestin silencing inhibited the
migration of breast CSC in vitro.Breast CSC migration is commonly associated with spon-
taneous EMT process. To investigate the potential mecha-
nisms underlying the poor migration of Nestin-si CSC, we
analyzed the relative levels of EMT-related molecules and
metastatic regulators in Nestin-c and Nestin-si CSC by
western blotting. The relative levels of N-cadherin, vimen-
tin, and a-SMA expression were significantly lower in
Nestin-si CSC than that in Nestin-c CSC, whereas the
levels of E-cadherin were significantly higher (P <0.05,
Figure 4B). Furthermore, significantly reduced levels of
MMP2, MMP9 and VEGF were detected in Nestin-si CSC,
when compared to Nestin-c CSC (P <0.05, Figure 4C).
Together, these data indicate that knockdown of Nestin
inhibited spontaneous EMT in breast CSC, contributing to
their reduced invasiveness.
Nestin silencing inhibits the Wnt/β-catenin signaling in
breast CSC
Breast CSC proliferation and migration are regulated
by a range of signaling pathways, including the Wnt/β-
catenin pathway. We therefore examined the impact of
Figure 4 Nestin silencing inhibits breast CSC migration by modulating the expression of EMT-related genes (A). The migration of Nestin-si and
Nestin-c breast CSC. Nestin-si and Nestin-c breast CSC were incubated in the upper chambers of transwell plates at 37 °C for 1.5 h. The migrated cells
were stained with crystal violet and counted. Results are presented as mean ± SD of the numbers of migrated cells per group of cells. (B) and (C). The
relative levels of EMT-related protein expression in CSC. Nestin-si and Nestin-c breast CSC were incubated for 48 h, and the relative levels of EMT-related
proteins to β-actin were determined by western blot analysis. Data shown are representative images and expressed as the mean ± SD of each target
protein in each type of cells from six separate experiments. *P <0.05 vs. the Nestin-c. CSC, cancer stem cell; EMT, epithelial-mesenchymal transition;
SD, standard deviation.
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breast CSC by western blotting (Figure 5A). The relative
levels of Axin, GSK-3β, and APC in Nestin-si CSC were
significantly higher than that in Nestin-c CSC (P <0.05,
Figure 5A). A similar pattern of the relative levels of
mRNA transcripts of these genes was detected in
Nestin-si and Nestin-c CSC (data not shown). The
relative levels of nuclear and cytoplasmic β-catenin, as
well as the ratio of nuclear to cytoplasmic β-catenin,
were significantly lower in Nestin-si cells than in
Nestin-c CSC (P <0.05, Figure 5A).
The relative levels of c-Myc, cyclin D1, and MMP-7
were significantly lower in Nestin-si CSC than that in
Nestin-c CSC, while the relative levels of PPARa andGSK-3β expression and GSK-3β phosphorylation were
significantly higher in Nestin-si CSC than that in Nestin-c
CSC (P <0.05, Figure 5B, C). Finally, we employed the
mammosphere assay to determine the importance of
the Wnt/β-catenin signaling in the proliferation of CSC.
We found that treatment with LGK974, an inhibitor of the
PORCN-related Wnt/β-catenin signaling pathway, sig-
nificantly inhibited the formation of Nestinhigh-mediated
mammospheres; however, treatment with SB216763,
an inhibitor of GSK-3β, significantly enhanced the for-
mation of Nestinlow-mediated mammospheres in vitro
(P <0.05 for both, Figure 5D). These data indicate that
Nestin silencing inhibits Wnt/β-catenin activation, which
is crucial for the proliferation of breast CSC.
Figure 5 Nestin silencing inhibits the Wnt/β-catenin signaling in breast CSC. Nestin-si and Nestin-c breast CSC were cultured for 48 h,
and the relative levels of target proteins and phosphorylation were determined by western blotting. Data are presented as the mean ± SD
of the levels of target proteins vs. the β-actin control, or the phosphorylated vs. the total form, from six separate experiments. In addition,
Nestinhigh in the presence or absence of LGK974 (1 nM), Nestinlow in the presence or absence of SB216763 (5 μM), and control CSC were
tested for their proliferation via mammosphere formation assays. Western blot analysis. (A-C). Quantitative analysis of the relative levels of
target proteins. (D) Quantitative analysis of the formed mammospheres. *P <0.05, vs. the Nestin-c or control, except for specifically indicated.
CSC, cancer stem cell; SD, standard deviation.
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Previous studies have shown that Nestin expression is
associated with the disease progression and poor prog-
nosis in breast cancers, particularly for those with ad-
vanced lymph node metastasis [16,36]. In this study, we
examined Nestin expression in 150 specimens of triple-
negative breast cancers, and found that 41 (27.33%) out
of them were positive for anti-Nestin staining. Import-
antly, Nestin expression was significantly associated with
poor survival in patients with triple-negative breast can-
cer. To the best of our knowledge, this is the first report
of an association between Nestin expression and disease
prognosis in Chinese patients with triple-negative breast
cancer. These novel data extend previous findings in
other populations, and support a role for Nestin in pro-
moting disease progression. Therefore, Nestin may be a
therapeutic target and prognostic biomarker for triple-
negative breast cancer.
Nestin is known to be a neural stem cell marker, and
is expressed in CSC [37], which play important roles in
the progression and metastasis of breast cancer [16]. In this
study, we identified that breast Nestinhigh, but not Nestinlow
CSC had potent tumorigenicity, as evidenced by rapid
mammosphere formation in vitro and efficient induction of
solid tumors in vivo, consistent with our previous observa-
tions [38]. Similarly, Nestin-overexpressing Nestin+, but not
Nestin-silenced Nestin-si CSC effectively formed mammo-
spheres. Nestin silencing induced cell cycle arrest at G2/M
phrase and promoted the spontaneous apoptosis of Nestin-
si CSC. These findings extended previous observations
where downregulation of Nestin expression inhibited
the proliferation of melanoma cells in vitro [39], and
the growth of implanted pancreatic tumors in vivo
[40]. Our findings suggest that Nestin may enhance the
proliferation and survival of breast CSC, contributing
to the progression of triple-negative breast cancer.
Cancer metastasis is associated with poor prognosis
of triple-negative breast cancer. In breast CSC, the
EMT process is related to increased invasiveness and
metastatic potential [26]. We observed that Nestin si-
lencing mitigated the invasiveness of Nestin-si CSC,
which was associated with significantly reduced levels
of N-cadherin, vimentin and a-SMA, but increased
levels of E-cadherin in breast CSC. In addition, Nestin
silencing significantly reduced the relative levels of
MMP2, MMP9, and VEGF in breast CSC. Together,
our results indicate that Nestin silencing inhibits spon-
taneous EMT in breast CSC. Previous studies have
showed that increased levels of EMT and expression of
stemness markers are associated with progression and
metastasis of invasive breast cancer, including triple-
negative breast cancer [16,36]. Our findings therefore
suggest that Nestin may be a potential therapeutic tar-
get for the prevention of breast cancer metastasis. Weare interested in further investigating the molecular
mechanisms by which Nestin regulates the EMT
process in breast CSC.
The Wnt/β-catenin pathway regulates the proliferation
and tumorigenicity of stem cells.
Evidently, induction of Wnt/β-catenin overexpression
enhances the tumorigenicity of breast CSC [32]. In this
study, we found that knockdown of Nestin expression
significantly increased the levels of Axin, GSK-3β, and
APC, and the ratios of cytoplasmic to nuclear β-catenin
in breast CSC. Knockdown of Nestin expression signifi-
cantly reduced the relative levels of c-Myc, cyclin D1, and
MMP-7, but increased the relative levels of inhibitory
PPARa in breast CSC. Clearly, Nestin silencing inhibited
the Wnt/β-catenin activation in breast CSC, leading to poor
proliferation, invasiveness, and cell cycle arrest of CSC.
Importantly, we also found that inhibition of PORCN to
mitigate spontaneous Wnt secretion and the Wnt/β-ca-
tenin activation significantly reduced the proliferation of
Nestinhigh CSC, while inhibition of GSK-3 promoted the
proliferation of Nestinlow CSC in vitro. These data clearly
indicate that spontaneous Wnt/β-catenin activation was
crucial for Nestin to promote CSC proliferation, and fur-
ther supported the notion that GSK-3β is a negative regula-
tor of the Wnt/β-catenin activation in CSC [41]. Since
Nestin has no intrinsic phosphatase or protease activity, it
is unlikely that Nestin directly mediates the degradation of
phosphorylated GSK-3β. Indeed, many pathways, such as
the ERK and PI3K/AKT pathways, can phosphorylate GSK-
3β and downregulate its activity [42,43]. It is possible that
Nestin regulates the Wnt/β-catenin pathway by indirectly
affecting the activity of GSK-3β in breast CSC. We are
interested in further investigating how Nestin regulates
GSK-3β and Wnt/β-catenin activation in breast CSC.
Conclusions
Our data indicated that Nestin expression in breast can-
cer tissues was associated with poor survival of Chinese
patients with triple-negative breast cancer. Furthermore,
Nestinhigh, but not Nestinlow breast CSC, had potent
tumorigenicity to form mammospheres in vitro, and
to induce solid tumors in vivo. Knockdown of Nestin
expression inhibited the proliferation and invasiveness,
but enhanced the spontaneous apoptosis of breast CSC.
Nestin silencing inhibited the spontaneous process of
EMT and the Wnt/β-catenin activation in breast CSC.
Our data therefore suggest that Nestin may be a poten-
tial therapeutic target for triple-negative breast cancer.
Our findings may provide new insights into the roles of
Nestin in regulating key cellular processes in breast
CSC. Although this study examined a relatively small
number of breast tumor samples, our findings extended
previous observations to confirm the importance of
Nestin expression in the prognosis of triple-negative
Zhao et al. Breast Cancer Research 2014, 16:408 Page 11 of 12
http://breast-cancer-research.com/content/16/1/408breast cancer. While we did not define the precise mo-
lecular mechanisms by which Nestin promoted the
Wnt/β-catenin activation in breast CSC, our data clearly
indicated that spontaneous Wnt/β-catenin activation was
crucial for Nestin to promote CSC proliferation, which
was negatively regulated by GSK-3β. We are interested in
further investigating how Nestin inhibits the growth and
metastasis of breast cancers in vivo. Therefore, further
studies are warranted to validate these findings in a larger
population.
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